Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD-III): a randomized controlled trial for clinical outcomes

Int Urol Nephrol. 2016 Nov;48(11):1897-1909. doi: 10.1007/s11255-016-1415-8. Epub 2016 Sep 12.

Abstract

Purpose: Fluid management with body composition monitor based on bioimpedance spectroscopy (BCM-BIS) has been found to be beneficial for dialysis patients. We conducted a study to provide an algorithm for the determination of post-dialysis target weight (PDTW) and to evaluate whether this approach could improve clinical outcomes compared to patients who had PDTW decided clinically.

Methods: Two hundred and ninety-eight dialysis patients participated in this 1-year randomized controlled trial. The outcomes were all-cause hospitalization rate, AFO or CV-related events, hypertension and intra-dialysis morbidities.

Results: 80 % of post-dialysis weight reached the target set with current algorithm. All-cause hospitalization rate was not different. Incidence of acute fluid overload (AFO) or CV-related events was lower in study group. Longitudinal data showed decreased incidence of hypertension, intra-dialysis morbidities and intra-dialysis hypotension.

Conclusions: Assessment of PDTW by BCM-BIS with an explicit algorithm decreased AFO or CV-related events, hypertension and intra-dialysis morbidities. Further studies were required to demonstrate possible benefits of hospitalization rate.

Keywords: Bioimpedance spectroscopy; Body composition monitor; Hemodialysis; Intra-dialysis morbidities.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Algorithms*
  • Asian People
  • Body Composition
  • Body Fluids*
  • Body Weight
  • Electric Impedance*
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Hypertension / etiology
  • Hypotension / etiology
  • Male
  • Middle Aged
  • Prospective Studies
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods
  • Signal Processing, Computer-Assisted
  • Taiwan
  • Time Factors